Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
International Sweetene...International Sweetener Colloquium
Not Confirmed
Not Confirmed
22-25 February, 2026
Not Confirmed
Not Confirmed
23-25 February, 2026
Clinical Trial Supply ...Clinical Trial Supply Europe
Not Confirmed
Not Confirmed
24-25 February, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
International Sweetener Colloquium
Not Confirmed
Contact SupplierInternational Sweetener Colloquium
International Sweetene...International Sweetener Colloquium
Industry Trade Show
Not Confirmed
22-25 February, 2026
Industry Trade Show
Not Confirmed
23-25 February, 2026
Clinical Trial Supply ...Clinical Trial Supply Europe
Industry Trade Show
Not Confirmed
24-25 February, 2026
Digital content
NEWS #PharmaBuzz
13 Feb 2026
// EXPRESSPHARMA
https://www.expresspharma.in/akums-receives-first-uk-mhra-approval-for-rivaroxaban/
27 Jan 2026
// EXPRESSPHARMA
https://www.expresspharma.in/akums-strengthens-presence-in-regulated-markets-with-eu-gmp-approvals-for-2-haridwar-plants/
29 Dec 2025
// INDPHARMAPOST
https://www.indianpharmapost.com/rd/akums-and-sharda-university-ink-mou-to-bridge-industryacademia-gap-18711
15 Dec 2025
// INDPHARMAPOST
https://www.indianpharmapost.com/news/akums-launches-advanced-gabapentin-er-for-phn-management-with-retenex-technology-18559
28 Nov 2025
// INDPHARMAPOST
https://www.indianpharmapost.com/people/akums-drugs-appoints-yuvraj-datta-as-president-operational-strategy-excellence-18386
13 Nov 2025
// BUSINESS STD
https://www.business-standard.com/companies/news/akums-q2-pat-falls-35-8-on-muted-cdmo-biz-growth-declining-api-prices-125111302120_1.html
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Registration Number : 228MF10044
Registrant's Address : S. C. O. 99-100, 3rd & 4th Floor, Sector 17-B, Chandigarh-160017, INDIA
Initial Date of Registration : 2016-02-08
Latest Date of Registration :
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Registration Number : 223MF10157
Registrant's Address : S. C. O. 99-100, 3rd & 4th Floor, Sector 17-B, Chandigarh-160017, INDIA
Initial Date of Registration : 2011-11-02
Latest Date of Registration :
Registrant Name : Essel Bio Co., Ltd.
Registration Date : 2013-12-27
Registration Number : 20120907-25-A-270-06(1)
Manufacturer Name : Parabolic Drugs Ltd
Manufacturer Address : Village Sundhran, Post office : Mubarakpur, Tehsil : Derabassi, District : Mohali, Punjab, India.
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Certificate Number : R1-CEP 2004-266 - Rev 01
Issue Date : 2012-11-16
Type : Chemical
Substance Number : 260
Status : Withdrawn by EDQM F...
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Certificate Number : R0-CEP 2011-090 - Rev 00
Issue Date : 2013-03-07
Type : Chemical
Substance Number : 167
Status : Withdrawn by EDQM F...
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Certificate Number : R0-CEP 2011-083 - Rev 00
Issue Date : 2013-03-07
Type : Chemical
Substance Number : 168
Status : Withdrawn by EDQM F...
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Certificate Number : R0-CEP 2011-106 - Rev 00
Issue Date : 2012-10-11
Type : Chemical
Substance Number : 808
Status : Withdrawn by EDQM F...
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25219
Submission : 2011-08-16
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Certificate Number : R0-CEP 2010-350 - Rev 00
Issue Date : 2013-07-04
Type : Chemical
Substance Number : 661
Status : Withdrawn by EDQM F...
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Certificate Number : R0-CEP 2010-311 - Rev 00
Issue Date : 2013-01-24
Type : Chemical
Substance Number : 668
Status : Withdrawn by EDQM F...
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Certificate Number : R0-CEP 2009-295 - Rev 00
Issue Date : 2011-06-01
Type : Chemical
Substance Number : 852
Status : Withdrawn by EDQM F...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25219
Submission : 2011-08-16
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
CEP/COS
Certificate Numbers : R1-CEP 2004-266 - Rev 01
Status : Withdrawn by EDQM F...
Issue Date : 2012-11-16
Type : Chemical
Substance Number : 260
CEP/COS
Certificate Numbers : R0-CEP 2011-090 - Rev 00
Status : Withdrawn by EDQM F...
Issue Date : 2013-03-07
Type : Chemical
Substance Number : 167
CEP/COS
Certificate Numbers : R0-CEP 2011-083 - Rev 00
Status : Withdrawn by EDQM F...
Issue Date : 2013-03-07
Type : Chemical
Substance Number : 168
CEP/COS
Certificate Numbers : R0-CEP 2011-106 - Rev 00
Status : Withdrawn by EDQM F...
Issue Date : 2012-10-11
Type : Chemical
Substance Number : 808
CEP/COS
Certificate Numbers : R0-CEP 2010-350 - Rev 00
Status : Withdrawn by EDQM F...
Issue Date : 2013-07-04
Type : Chemical
Substance Number : 661
CEP/COS
Certificate Numbers : R0-CEP 2011-052 - Rev 00
Status : Withdrawn by EDQM F...
Issue Date : 2013-01-11
Type : Chemical
Substance Number : 663
Certificate Numbers : R0-CEP 2005-064 - Rev 00
Status : Expired
Issue Date : 2007-07-12
Type : Chemical
Substance Number : 668
Certificate Numbers : R0-CEP 2010-311 - Rev 00
Status : Withdrawn by EDQM F...
Issue Date : 2013-01-24
Type : Chemical
Substance Number : 668
CEP/COS
Certificate Numbers : R0-CEP 2009-295 - Rev 00
Status : Withdrawn by EDQM F...
Issue Date : 2011-06-01
Type : Chemical
Substance Number : 852
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Rivaroxaban, a miscellaneous product targeting coagulation factor X, shows promise in treating thromboembolic disorders.
Lead Product(s): Rivaroxaban
Therapeutic Area: Hematology Brand Name: Rivarox V
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 13, 2026
Lead Product(s) : Rivaroxaban
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Akums Gets First UK MHRA Approval for Rivaroxaban
Details : Rivaroxaban, a miscellaneous product targeting coagulation factor X, shows promise in treating thromboembolic disorders.
Product Name : Rivarox V
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 13, 2026
Details:
Paracetamol oral suspension is an addition to the analgesic and antipyretic category by offering therapeutic adult dosing in a minimal volume.
Lead Product(s): Paracetamol
Therapeutic Area: Neurology Brand Name: Paracetamol
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 22, 2025
Lead Product(s) : Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Akums Launches High-Strength Paracetamol Oral Suspension 500mg/5ml
Details : Paracetamol oral suspension is an addition to the analgesic and antipyretic category by offering therapeutic adult dosing in a minimal volume.
Product Name : Paracetamol
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 22, 2025
Details:
Ripasudil-Timolol combination therapy is approved by the DCGI for glaucoma treatment in India and Akums becoming reportedly the first Indian CDMO to receive approval for this formulation.
Lead Product(s): Ripasudil,Timolol Maleate
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 01, 2025
Lead Product(s) : Ripasudil,Timolol Maleate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Akums Drugs Launches Ripasudil-Timolol Combination Therapy for Glaucoma in India
Details : Ripasudil-Timolol combination therapy is approved by the DCGI for glaucoma treatment in India and Akums becoming reportedly the first Indian CDMO to receive approval for this formulation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 01, 2025
Details:
Akums gains rights for patented topical formulation, Therapy-07, for the Indian market which combines three medicaments (finasteride,latanoprost,minoxidil) to combat alopecia.
Lead Product(s): Finasteride,Latanoprost,Minoxidil
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Recipient: Triple Hair
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 16, 2024
Lead Product(s) : Finasteride,Latanoprost,Minoxidil
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : Triple Hair
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Akums Drugs inks licensing pact with Canadian firm Triple Hair Inc
Details : Akums gains rights for patented topical formulation, Therapy-07, for the Indian market which combines three medicaments (finasteride,latanoprost,minoxidil) to combat alopecia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 16, 2024
Details:
Dual action heartburn relief chewable tablet, consisting Famotidine (H2 receptor antagonist), Calcium Carbonate and Magnesium Hydroxide have been approved and launched in indian market.
Lead Product(s): Famotidine,Calcium Carbonate,Magnesium Hydroxide
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 12, 2024
Lead Product(s) : Famotidine,Calcium Carbonate,Magnesium Hydroxide
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Akums Launches Dual Action Heartburn Relief Chewable Tablet
Details : Dual action heartburn relief chewable tablet, consisting Famotidine (H2 receptor antagonist), Calcium Carbonate and Magnesium Hydroxide have been approved and launched in indian market.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 12, 2024
Details:
Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase, indicated for treating gastric and duodenal ulcers, as well as GERD.
Lead Product(s): Rabeprazole Sodium,Levosulpiride
Therapeutic Area: Gastroenterology Brand Name: Rabeprazole-Levosulpiride-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 10, 2024
Lead Product(s) : Rabeprazole Sodium,Levosulpiride
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Akums Launches Rabeprazole + Levosulpiride SR Capsules for GERD in India
Details : Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase, indicated for treating gastric and duodenal ulcers, as well as GERD.
Product Name : Rabeprazole-Levosulpiride-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 10, 2024
Details:
DCGI has approved Tamsulosin (selective alpha1A-adrenergic receptor antagonist) + Tadalafil, a fixed dose combination within a hard gelatin capsule for the treatment of erectile dysfunction & benign prostatic hyperplasia.
Lead Product(s): Tamsulosin,Tadalafil
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 15, 2023
Lead Product(s) : Tamsulosin,Tadalafil
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Akums Introduces Tamsulosin + Tadalafil Capsule — to the Indian Market
Details : DCGI has approved Tamsulosin (selective alpha1A-adrenergic receptor antagonist) + Tadalafil, a fixed dose combination within a hard gelatin capsule for the treatment of erectile dysfunction & benign prostatic hyperplasia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 15, 2023
Details:
Sitagliptin, Pioglitazone & Metformin are combined for the treatment of diabetes. Metformin, coupled with the functional and corrective influence of pioglitazone on beta-cell and metabolic syndrome and the stability of Sitagliptin, make an effective solution for diabetes.
Lead Product(s): Sitagliptin Phosphate,Metformin,Pioglitazone
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 27, 2023
Lead Product(s) : Sitagliptin Phosphate,Metformin,Pioglitazone
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Akums Gets DCGI Nod for Triple Combination Diabetes Medication
Details : Sitagliptin, Pioglitazone & Metformin are combined for the treatment of diabetes. Metformin, coupled with the functional and corrective influence of pioglitazone on beta-cell and metabolic syndrome and the stability of Sitagliptin, make an effective solu...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 27, 2023
Details:
Akums and Lyrus will ensure the launch of patented drugs and more patient-friendly formulations, in the areas of pain, obesity, diabetes, psoriasis, seasonal flu, respiratory insufficiency, immunity and women’s health with a special focus on geriatric and pediatric population.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Undisclosed
Sponsor: Lyrus Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 22, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Lyrus Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Akums, Lyrus Life Sciences Collaborate for Patented Technologies and Formulations
Details : Akums and Lyrus will ensure the launch of patented drugs and more patient-friendly formulations, in the areas of pain, obesity, diabetes, psoriasis, seasonal flu, respiratory insufficiency, immunity and women’s health with a special focus on geriatric ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 22, 2023
Details:
Lobeglitazone is a film-coated tablet made up of Lobeglitazone Sulfate equivalent to Lobeglitazone to improve glycaemic control in adult type 2 diabetes.
Lead Product(s): Lobeglitazone
Therapeutic Area: Endocrinology Brand Name: Lobeglitazone-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 06, 2023
Lead Product(s) : Lobeglitazone
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Akums Receives DCGI Approval for Type 2 Diabetes Drug to Improve Insulin Resistance
Details : Lobeglitazone is a film-coated tablet made up of Lobeglitazone Sulfate equivalent to Lobeglitazone to improve glycaemic control in adult type 2 diabetes.
Product Name : Lobeglitazone-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 06, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Services
Drug Product Manufacturing
Injectable / Parenteral
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Inspections and registrations
ABOUT THIS PAGE
Share 
